Cancer Facts

Lifetime risks of breast, ovarian, endometrial, and colon cancers increase dramatically for women with hereditary cancer syndromes

BREAST CANCER
Approximately 1 in 8 women in the US will develop breast cancer over the course of her lifetime: 5-10% of breast cancers are thought to be hereditary [1-2]

OVARIAN CANCER
Societal guidelines recommend that every woman diagnosed with epithelial ovarian cancer be offered genetic testing [3]

50%

ENDOMETRIAL & COLON CANCER
Individuals with Lynch syndrome have a 50% chance to pass this cancer-predisposition syndrome to their children [4]

Common high-risk genes highlight the importance of hereditary cancer testing* [5-7]

Hereditary Breast & Ovarian Cancer
(associated genes: *BRCA1/BRCA2*)



Lynch syndrome
(associated genes: *MLH1, MSH2, MSH6, PMS2, EPCAM*)



Cancer risks range depending on the specific gene

Who should be screened for hereditary cancer?

- Cancer diagnosed before the age of 50, including breast, colon, or endometrial
- Ovarian, pancreatic, or triple negative breast cancer diagnosed at any age
- Multiple cancers in same individual (e.g., bilateral breast cancer) or on same side of family‡
- Ashkenazi Jewish ancestry

Recent studies in real world settings show that **20-26% patients meet standard guidelines for further evaluation,** including genetic testing [8-10]

*Other types of cancer can also be associated that are not listed

‡Family members including 1st, 2nd, and 3rd degree relatives

sema4

Hereditary cancer testing can significantly decrease cancer risks and improve survival rates by enabling personalized medical management strategies which may include:

- More frequent cancer screening often including multiple modalities, starting at earlier age
- Prophylactic risk-reducing surgery
- Risk-reducing medications

Additional benefits:

- ☑ Helpful information for patients and their partners in family planning decisions, especially when risk is identified during the reproductive years
- ☑ Meaningful information to share with family members

Multiple studies demonstrate the efficacy of increased screening and preventative surgeries for hereditary cancer syndromes



Enhanced screening may have **up to 2.5-fold increase in detecting cancer at an earlier stage,** thereby increasing the likelihood of successful treatment [11]

Bilateral prophylactic mastectomy has been shown **to reduce breast cancer risk by at least 95%** in women with a pathogenic variant in *BRCA1* or *BRCA2* [12-14]





Prophylactic salpingo-oophorectomy has been shown **to reduce ovarian cancer risk by 90%** in women at high risk due to a hereditary predisposition [15]

Best-in-class support and service, every step of the way

Sema4 provides comprehensive workflow options to seamlessly integrate with your practice. Our highly knowledgeable team is dedicated to partnering with practices such as yours to deliver the best possible care to patients.

- Proactive genetic counseling
- Patient identification & education tools
- Extensive network coverage & support
- Seamless workflow integration

To learn more about Sema4 Hereditary Cancer solutions and services, please visit **sema4.com/hc-obgyn**, call **833-486-6260**, or email **ClientServicesOncology@sema4.com**

References:
1. U.S. Breast Cancer Statistics. National Cancer Institute. Accessed Oct 1, 2020. https://www.breastcancer.org/symptoms/understand_bc/statistics;
2. American Cancer Society. Accessed August 13 2021. https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html
3. Konstantinopoulos, P., et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology 38, no. 11 (April 10, 2020) 1222-1245.
4. Lynch Syndrome. Accessed July 22, 2021. https://www.cancer.net/cancer-types/lynch-syndrome
5. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/;
6. Bonadona V, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011 Jun 8;305(22):2304-10;
7. Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. JAMA Oncol. 2017;3(12):1702–1706.
8. Doheny, et al. Hereditary cancer risk assessment using a chatbot in women presenting to obstetrics and gynecology practices across the U.S. [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-39;
9. Frezzo, T., et al. The genetic family history as a risk assessment tool in internal medicine. Genet Med 5, 84–91 (2003);
10. DeFrancesco MS, et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstet Gynecol. 2018 Nov;132(5):1121-1129;
11. Phi, XA. Et al. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis. J Clin Oncol. 2015 Feb 1;33(4):349-56.
12. Domchek SM, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304(9):967–975.
13. Rebbeck TR, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. Journal of Clinical Oncology 2004; 22(6):1055-1062.
14. Meijers-Heijboer H, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine 2001; 345(3):159-164.
15. Guillem JG, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Journal of Clinical Oncology 2006; 24(28):4642-4660.